http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
배성만 ( Seong Man Bae ),유빈 ( Bin Yoo ),김주현 ( Ju Hyeon Kim ),김민구 ( Min Gu Kim ),안영은 ( Young Eun Ahn ),김용길 ( Yong Gil Kim ),이창근 ( Chang Keun Lee ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
Pericarditis and atherosclerotic events are generally regarded as relatively common cardiac manifestations of rheumatoid arthritis(RA). However, RA-associated endocarditis is rarely reported, and can be confused (by clinicians) with an infective vegetation. Herein, we report a case of sterile endocarditis involving the mitral valve in a 36 year-old patient with longstanding RA; the problemwas accidentally detected during performance of a valve operation.(Korean J Med 2015;88:110-113)
정형외과 수술 후 5일간 투여 된 로페콕시브 50mg의 진통효과 -치료약 대조, 무작위배정, 다기관, 공개 임상시험-
김정만,김희중,배대경,서재곤,선두훈,성상철,이명철,이수호,조우신,조윤제,한창동,이우석,김강일,안진환,이석현,박윤수,Kim, Jung-Man,Kim, Hee-Joong,Bae, Dae-Kyung,Seo, Jai-Gon,Sun, Doo-Hoon,Seong, Sang-Cheol,Lee, Myung-Chul,Lee, Soo-Ho,Cho, Woo-Shin,Cho, 대한임상약리학회 2000 臨床藥理學會誌 Vol.8 No.2
Background: Nonsteroidal anti-inflammatory drugs(NSAIDs) inhibit both cyclooxygenase-1(COX1) and cyclooxygenase-2(COX-2). There have been several trials showing that a specific inhibitor of COX-2 provide efficacy in surgical pain comparable with NSAIDs. In this study, the efficacy and safety of the rofecoxib which specifically inhibits COX-2 were compared with aceclofenac, an NSAID, in patients with pain after orthopedic surgery. Method : A randomized, open, active comparator-controlled trial of 229 adults with orthopedic surgical pain was conducted. Patients were randomized to one of two treatment groups ; 50mg of rofecoxib once daily or 100mg of aceclofenac twice daily. Clinical efficacy and safety were evaluated over 5-day treatment period. Result : Rofecoxib at dosage of 50mg demonstrated efficacy that was clinically comparable to that of aceclofenac as assessed by primary endpoint(TOPAR8) according to predefined comparability criteria. Results from secondary endpoints(SPID8, patient global assessment of response to therapy) were consistent with those of the primary endpoint. All treatments were generally well tolerated. Conclusion : Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined equivalence margin, to that of 100mg of aceclofenac twice daily in this 5-day study.
임우영,오성희,이승환,박영민,배성만,Im, Woo-Young,Oh, Seong-Hee,Lee, Seung-Hwan,Park, Young-Min,Bae, Seong-Man 대한생물정신의학회 2008 생물정신의학 Vol.15 No.3
Objectives : The purpose of this study is to compare the ability of facial affect perception among schizophrenia patients, their first degree relatives, and normal control subjects. Methods : Thirty five patients with schizophrenia, 22 first degree relatives, and 34 normal control subjects were recruited in this study. All three groups were matched for age and education levels. The facial affect identification test(FAIT), and neurocognitive test were applied. In the FAIT, the correct response rate, perceived intensity, and sensitivity for 6 kinds of affects were compared among three groups. Results : We found that correct response rate of sadness and anger were decreased in the schizophrenia patients compared with the normal control group. Also the schizophrenia patients showed reduced sensitivity for all six affects compared with the normal control group. The ability of facial affect perception in first degree relatives of schizophrenia patients was decreased but there were not any significant differences compared with normal control group. Conclusion : This study confirmed significantly reduced ability of facial affect perception in schizophrenia patients compared with normal control. Decreased ability of facial affect perception in first degree relatives suggests that affective sensitivity can be influenced by genetic predisposition.